- Home
- TOPP vs SCYX Comparison
TOPP vs SCYX Comparison
Compare TOPP & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPP
- SCYX
- Stock Information
- Founded
- TOPP 2014
- SCYX 1999
- Country
- TOPP United States
- SCYX United States
- Employees
- TOPP N/A
- SCYX N/A
- Industry
- TOPP
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- TOPP
- SCYX Health Care
- Exchange
- TOPP NYSE
- SCYX Nasdaq
- Market Cap
- TOPP 26.6M
- SCYX 28.5M
- IPO Year
- TOPP 2025
- SCYX 2014
- Fundamental
- Price
- TOPP $2.15
- SCYX $0.70
- Analyst Decision
- TOPP
- SCYX
- Analyst Count
- TOPP 0
- SCYX 0
- Target Price
- TOPP N/A
- SCYX N/A
- AVG Volume (30 Days)
- TOPP 12.5K
- SCYX 187.5K
- Earning Date
- TOPP 08-11-2025
- SCYX 08-11-2025
- Dividend Yield
- TOPP N/A
- SCYX N/A
- EPS Growth
- TOPP N/A
- SCYX N/A
- EPS
- TOPP N/A
- SCYX N/A
- Revenue
- TOPP $16,117,227.00
- SCYX $2,630,000.00
- Revenue This Year
- TOPP N/A
- SCYX $410.22
- Revenue Next Year
- TOPP N/A
- SCYX $248.83
- P/E Ratio
- TOPP N/A
- SCYX N/A
- Revenue Growth
- TOPP 0.44
- SCYX N/A
- 52 Week Low
- TOPP $0.97
- SCYX $0.66
- 52 Week High
- TOPP $4.50
- SCYX $2.21
- Technical
- Relative Strength Index (RSI)
- TOPP N/A
- SCYX 41.70
- Support Level
- TOPP N/A
- SCYX $0.67
- Resistance Level
- TOPP N/A
- SCYX $0.74
- Average True Range (ATR)
- TOPP 0.00
- SCYX 0.04
- MACD
- TOPP 0.00
- SCYX 0.00
- Stochastic Oscillator
- TOPP 0.00
- SCYX 10.15
About TOPP TOPPOINT HOLDINGS INC
Toppoint Holdings Inc is a truckload services and solutions provider focused on the recycling export supply chain. The company operates in one operating segment where it derives its revenues from the delivery of truckload services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.